Clinical Trials Logo

Proctitis clinical trials

View clinical trials related to Proctitis.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06087718 Not yet recruiting - Quality of Life Clinical Trials

Feasibility of the Maastro Applicator in Rectal Cancer

Start date: July 2024
Phase: N/A
Study type: Interventional

The goal of this interventional pilot trial is to confirm that Maastro endoluminal HDR ( High Dose Radiation) contact brachytherapy boosting is feasible and may increase the chance of functional organ sparing of the rectum in patients with rectal cancer. Participants will be treated with chemoradiotherapy and an endoluminal boost with the Maastro applicator.

NCT ID: NCT04918992 Not yet recruiting - Pelvic Cancer Clinical Trials

Post Radiotherapy MRI Based AI System to Predict Radiation Proctitis for Pelvic Cancers

MRI-RP-2021
Start date: June 22, 2021
Phase:
Study type: Observational

In this study, investigators utilize a Artificial Intelligence (AI) supportive system to predict radiation proctitis for patients with pelvic cancers underwent radiotherapy. By the system, whether the participants achieve the radiation proctitis will be identified based on the radiomics features extracted from the post radiotherapy Magnetic Resonance Imaging (MRI) . The predictive power to discriminate the radiation proctitis individuals from non-radiation proctitis patients, will be validated in this multicenter, prospective clinical study.

NCT ID: NCT04680195 Not yet recruiting - Clinical trials for Chronic Radiation Proctitis

Thalidomide in the Treatment of Chronic Radiation Proctitis With Intractable Bleeding

Thal-CRP
Start date: December 14, 2020
Phase: Phase 2
Study type: Interventional

Chronic radiation proctitis (CRP) is the main secondary toxic injury after pelvic radiotherapy. Hematochezia is the most common symptom for more than 80% of CRP patients. Non-surgical treatment is the first choice to the treatment of CRP to avoid the occurrence of serious complications. Conventional oral medication for the treatment of bleeding CRP is very few and has little effect. At present, no oral medication has been found to significantly alleviate and control refractory bleeding of CRP. Therefore, it is an urgent problem to screen out a drug that is more effective, safe and highly compliant for the treatment of hemorrhagic CRP. Thalidomide has anti-inflammatory, immune regulation, anti-angiogenesis and other effects. For the patients of CRP with intractable bleeding, a prospective, open clinical trial will be carried out to observe the safety and effectiveness of thalidomide in treating hemorrhagic CRP.

NCT ID: NCT02233933 Not yet recruiting - Rectal Bleeding Clinical Trials

Trial of Argon Plasma Coagulation Versus APC and APC and Hemospray in the Treatment of Radiation Proctitis

Start date: September 2014
Phase: N/A
Study type: Interventional

Randomized trial of Argon Plasma Coagulation compared with Argon Plasma Coagulation and Hemospray in the therapy of bleeding from Radiation Proctitis